Symfi, Symfi Lo, and Cimduo for HIV (online only)
Symfi, Symfi Lo, and Cimduo for HIV (online only)
January 14, 2019 (Issue: 1563)
The FDA has approved three new once-daily fixed-dose
antiretroviral drug combinations for treatment of HIV-1 infection. Symfi and Symfi Lo (Mylan) contain the
non-nucleoside reverse transcriptase inhibitor (NNRTI)
efavirenz and the nucleoside...more
- A once-daily combination tablet (Atripla) for HIV. Med Lett Drugs Ther 2006; 48:78.
- Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: aidsinfo.nih.gov. Accessed January 4, 2019.
- JE Gallant et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191.
- ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 2014; 383:1474.
- ENCORE1 Study Group. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 2015; 15:793.
- Drugs for HIV infection. Treat Guidel Med Lett 2014; 12:7.
- FS Sarfo et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother 2014; 69:491.
- PE Sax et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606.
- A Hill et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad 2018; 4:72.
- N Ford et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2014; 28 (Suppl 2):S123.
- Panel of Antiretroviral Guidelines for Adults and Adolescents. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. Department of Health and Human Services. Available at: aidsinfo.nih.gov. Accessed January 4, 2019.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- RL Woosley et al. QT drugs list. Available at: www.crediblemeds. org. Accessed January 4, 2019.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Symfi, Symfi Lo, and Cimduo for HIV (online only)
Article code: 1563d
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
